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Background: Young children are one of the most vulnerable groups who may be infected 
with cholera. The following literature review of the efficacy of the currently available cholera 
vaccines provides a clear evidence base for the clinical administration of cholera vaccine, 
particularly in an epidemic situation.
Aim: To assess the efficacy of oral cholera vaccines in preventing cases of cholera in young 
children.
Methods: A systematic literature review was undertaken for the period 1983 to 2011 using 
PubMed and the search terms “oral cholera vaccines,” “children,” and “efficacy,” limited to 
“clinical trials” and “human studies”.
Results: Oral cholera vaccine provides an acceptable level of protection in young children, with 
the level of protection being greater at 12 or 24 months following immunization.
Conclusions: Children exposed to a potential risk of cholera are recommended to be vaccinated 
with an oral cholera vaccine, irrespective of whether its constituents include the B subunit.
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Introduction
cholera epidemiology worldwide,  
young children (,5 years)
Cholera is one of the most severe infectious diseases experienced by children in 
resource-poor regions of the world, causing a rapidly dehydrating diarrheal disease of 
mild-to-moderate severity in approximately 90% of cases, with a case-fatality rate of 
less than 5%.1 In endemic areas (Africa, Asia, South America, and Central America), 
infection with cholera results in 3–5 million cases and 100,000–130,000 deaths per 
year.2 Young children, aged less than 5 years, are one of the most vulnerable groups, 
with an annual incidence rate of cholera 2–4 times higher3 than those found in the 
overall population.
Types of cholera vaccines
In the early part of the 20th century the injectable killed whole cell vaccination was 
a required vaccine to enable entry into some countries. Nevertheless this vaccine has 
not been recommended for many years due to the limited protection and efficacy it 
afforded, the known side effects and the need for frequent boosters and importantly, 
the concomitant improvements in public health.4
In 1997 a variant whole cell vaccine (vWC) was licensed (ORCVAX®) in Vietnam 
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vaccine was modified (mORCVAX®) to a bivalent vaccine 
with the high toxin-producing strain being replaced by two 
Vibrio cholerae strains and including a double quantity of 
lipopolysaccharide antigen and so replaced the vWC which 
is no longer available.
Two oral cholera vaccine formulations are currently licensed 
and available in certain countries: a whole cell plus recombinant 
B subunit vaccine (WC-rBS); and the bivalent whole cell vac-
cine (BivWC).5 Both vaccines are administered according to 
a schedule which consists of two doses administered 2 weeks 
apart which provides protection for 2 years.
The WC-rBS (Dukoral®) is a monovalent vaccine com-
posed of three strains (classical and El Tor, Inaba and Ogawa) 
of heat and formalin-killed V . cholerae O1 with an additional 
purified cholera B subunit. Originally the B subunit of cholera 
toxin was produced chemically as part of the development of 
the whole cell plus B subunit vaccine (WC-BS), but currently 
the vaccine is produced using recombinant technology. The 
immune response of WC-BS and WC-rBS is practically identi-
cal, resulting in the WC-BS cholera vaccine no longer being 
available.1 The WC-rBS has been licensed for use in adults 
and children aged 2 to 65 years in more than 60 countries and 
this vaccine is the only one that may provide limited protection 
against enterotoxigenic Escherichia coli2 in travelers.6
The BivWC (Shanchol®) is a bivalent vaccine composed 
of three strains (classical and El Tor, Inaba and Ogawa) of heat 
and formalin-killed V . cholerae O1 with an additional strain 
of formalin-killed V . cholerae O139. It is licensed for use in 
India for adults and children aged 1 year and over.
The vWC and BivWC vaccines do not contain the bacte-
rial toxin B subunit and neither requires a buffer for admin-
istration, so making the vaccine less expensive and easier to 
store as less storage space is required but these vaccines do 
not provide any protection against enterotoxigenic E. coli as 
one cause of travelers’ diarrhea.
A recent meta-analysis7 evaluating oral whole cell 
cholera vaccines but without including age cohorts, dem-
onstrated an efficacy of 52% (95% confidence interval [CI]: 
35%–65%) in the first year and 61% (95% CI: 50%–70%) 
within the second year of follow-up independent of the 
type of vaccine administered. As young children are one 
of the most vulnerable groups, who may become seriously 
ill when exposed to infection with cholera, we completed a 
literature review of the efficacy of cholera vaccines in this 
high-risk population.
Material and methods
A systematic review of the literature was undertaken for the 
period 1983 to 2011 using PubMed and  the search terms 
“oral cholera vaccines,” “children,” and “efficacy,” but 2011 
and limited to “clinical trials” and “human studies”. The 
review included a prescreening of the manuscripts by title 
and content of the abstracts and these were then assessed in 
terms of eligibility by reading the full text. Only those studies 
that described the efficacy of oral whole cell cholera vaccines 
in children and gave information about the clinical outcome 
(cases of cholera) and reported the raw data stratified by age 
(#5 years, .5 years old) were included in the review. The 
review was performed on the efficacy of whole cell cholera 
vaccines in indigenous children.
The design and possible limitations of the studies were 
assessed using the criteria applied to randomized control 
trials (CONSORT guidelines). The main possible limita-
tions considered included any bias because of information, 
selection, or confounding, which may have led to the over- or 
underestimation of vaccine efficacy.
Vaccine efficacy was calculated using 95% CI using the 
following formula: (1 – relative risk) × 100.8 The relative 
risk was expressed as incidence of cholera in vaccinees as 
compared to incidence of cholera in the placebo group.
Results
The first search resulted in the identification of 38 studies 
from more than 100 papers and no further papers were 
included following a comprehensive screening of the refer-
ences. Several papers9–15 which described only the results 
of interim analyses rather than a full review of a study were 
excluded from this review.16 Similarly, twelve papers which 
focused on immunogenicity and safety without providing 
data regarding efficacy were not included.17–26 Consequently, 
four clinical trials involving oral whole cell cholera vaccines 
were reviewed as follows: WC-BS,27 WC-rBS,28 vWC,29   
and BivWC.30 In order to review the optimal evidence base, 
this review paper was only based on clinical trial data and 
observational studies were not included.
The study population consisted of indigenous popula-
tions of children residing in endemic countries and who were 
at risk of infection with cholera. Travelers as an at risk group 
were not considered as part of this review because clinical 
trials have not been completed in this particular cohort. 
The four studies included approximately 278,000 people, 
with approximately 96,000 children aged 1–15 years living 
throughout Asia and South America (Table 1). Each trial 
included at least 10,000 children living in a non-outbreak 
area, with the exception of one study by Trach et al.29 These 
trials provided results for each age group, type of oral cholera 
vaccine administered as well as for each year of follow-up, 
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In 1985, Clemens et al27 conducted a randomized 
double-blind controlled trial including follow-up over a 
period of 3 years to assess the protective efficacy of three 
doses of WC-BS or killed whole cell only oral cholera 
vaccines administered at 6-week intervals against placebo 
(E. coli K12) among 62,285 children and women residing 
in rural Bangladesh. Only 20,705 people received the 
WC-BS vaccine and 61.8% (n = 12,708) were children aged 
2–15 years. Efficacy was defined through different outcomes 
based on cases of cholera (symptomatic and asymptomatic), 
deaths of all causes, and cholera deaths in vaccinees who 
received WC-BS as compared with the placebo group. The 
data were stratified according to age: 2–5 years of age or 
older than 5 years; and follow-up was undertaken after the 
at first, second, and third year.
From 1993 to 1995, Taylor et al28 conducted a randomized 
double-blind controlled trial with a follow-up of 2 years 
to assess the protective efficacy of two doses of WC-rBS 
administered at 2-week intervals followed by a booster 
10 months later as compared against placebo (E. coli K12) 
among 14,997 children and adults up to 65 years old residing 
in marginal neighborhoods in Lima, Peru. Only 7594 people 
received the WC-BS vaccine of which 53.9% (n = 4096) were 
children aged 2–15 years old. The efficacy of the vaccine 
was defined by different outcomes based on cases of cholera 
and level of dehydration according to the World Health 
Organization definitions. These outcomes were identified 
through active household or passive surveillance, the latter 
being completed at health centers. The data were stratified 
by age: 2–5 years of age or older than 5 years; and follow-up 
was undertaken after the first and second year.
In 1992, Trach et al29 conducted a nonrandomized open-la-
bel trial during an outbreak of El Tor cholera with a follow-up 
of 1 year to assess the protective efficacy of two doses of vWC 
administered at 2-week intervals as compared with placebo 
(E. coli K12) among 134,453 residents aged 1 year or more 
in urban Vietnam (Hue). Half of the population (n = 67,395) 
received the vWC vaccine and 22.6% (n = 15,253) were chil-
dren aged 2–10 years old. The efficacy was defined by differ-
ent outcomes based on cases of cholera or diarrhea requiring 
inpatient care, or deaths from cholera. The data were stratified 
using the following age groups: 1–5 years, 6–10 years, 11–20 
years, 21–40 years, and older than 40 years; no results were 
reported regarding the follow-up period.
In 2006, Sur et al30 conducted a cluster randomized 
double-blind controlled trial with a follow-up of 2 years to 
assess the protective efficacy of two doses of bivalent vaccine 
(BivWC) administered at 2-week intervals as compared 
with placebo (E. coli K12) among 66,900 residents aged 1 
year or more in urban India (Kolkata). Only 31,932 people 
received BivWC of which 28.5% (n = 9,105) were children 
aged 1–14.9 years old. The efficacy was defined by differ-
ent outcomes based on cases of cholera (first symptomatic 
cholera episode confirmed by fecal excretion of V . cholerae 
O1 during a nonbloody diarrheal episode) and deaths of all 
causes in vaccinees as compared with the placebo group. The 
data were stratified by age group: 1–4.9 years, 5–14.9 years, 
and 15 years or older. The data obtained with reference to 
the second year of follow-up were only stratified by the age 
of the population only and results regarding the first year of 
follow-up were unpublished and unavailable.
Assessment of vaccine efficacy
Appreciating the heterogeneity of the study methodologies 
applied and the different oral cholera vaccines administered, 
the majority of these studies showed an overall protection 
up to 2 years following vaccination, ranging from 45% to 
77% in the overall population and between 38% and 52% 
in young children.
In the first year of follow-up, vaccine efficacy ranged from 
-4% to 66%, with the Taylor study confirming the rarity of 
cholera infection events globally. With respect to the age 
of the population, this review shows consistently lowered 
efficacy of the vaccine in children, with a decrease of 5% to 
40% in young children (#5 years old) compared with the 
overall population (.5 year old).
During the second year of follow-up, the efficacy of 
oral cholera vaccine ranged from 58% to 77% with a slight 
increase after the first year of follow-up. With regard to the 
age of population, a lower efficacy of oral cholera vaccine 
was evident, with a decrease of 10% to 31% in young chil-
dren (#5 years old) as compared with the overall population 
(.5 year old). An increase in efficacy was evident a year 
after administration of the vaccine.
The whole cell plus B subunits cholera vaccines (WC-BS 
and WC-rBS) appear to demonstrate less efficacy during the 
first year following administration of the vaccine in young 
children, but higher efficacy in the second year as compared 
with either the BivWC or vWC cholera vaccines. Further 
studies are required to confirm this finding, which may be due 
to imbalances in the O1 lipopolysaccharide antigen content 
in the both vaccines.
No other efficacy outcomes could be reviewed due to the 
absence of stratified data by age groups in each study.
In conclusion, the overall efficacy of oral cholera vaccines 
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systematically observed in young children (#5 years old) 
than as compared with the overall population.
Discussion
Individual studies have showed that the overall efficacy of 
oral whole cell vaccines against cholera is slightly higher 
at 24 months than at 12 months following administration.28 
Nevertheless the efficacy of an oral cholera vaccine in vul-
nerable populations remains inadequate and further analyses 
(meta-analysis) are recommended to understand this.
A herd immunity effect has been described in children 
in Bangladesh who were too young to be vaccinated with 
the WC-BS cholera vaccine; vaccinating only 50% of the 
population could result in a 93% reduction in the incidence 
of cholera in the whole population.31–33 It is postulated that 
any of the available oral cholera vaccines could provide a 
herd immunity effect for at-risk populations.
One of the problems with the review of these studies 
was the inclusion of possible biases as although this review 
includes data analyzed systematically by age groups, a 
meta-analysis for each age group was not available for 
inclusion or therefore for review.29,30
Other limitations in this review includes the fact that 
some of the excluded studies were based on immunogenicity 
or safety data but none of them published data on efficacy 
by age group.
Furthermore, consideration of the different types of oral 
whole cell vaccines studied as well as different study settings 
and vague or different case definitions, could explain the 
heterogeneity of the available results, which could have led 
to either over- or underestimation of vaccine efficacy.
Conclusion
The whole cell oral cholera vaccine provides an acceptable 
level of efficacy in young children, which is estimated 
to be lower than in the overall population following the 
first and second year of administration of the vaccine. A 
mathematical modeling approach is highly recommended 
in order to determine the efficacy of oral cholera vaccine 
before more specific conclusions can be drawn on oral 
cholera vaccine efficacy in this specific group. Neverthe-
less, more studies are required to develop this model and 
to evaluate the effect of herd immunity as a plausible 
explanation of these findings.
It could also be hypothesized that oral cholera vaccine 
might decrease the incidence of cholera in children as well 
as in the overall population. Such a hypothesis requires 
further blinded and randomized studies in children who 
would receive oral whole cell vaccines as compared with a 
non-indigenous populations.
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